Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study. - Wikidata - wikimedia - TriplyDB

Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study.

Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study.

http://www.wikidata.org/entity/Q35757641

about

Mesenchymal stem cells: environmentally responsive therapeutics for regenerative medicine The role of stem cell therapy in multiple sclerosis: An overview of the current status of the clinical studies Stem Cell Imaging: Tools to Improve Cell Delivery and Viability.Mesenchymal stem cells and immunomodulation: current status and future prospects Mesenchymal stem cells for the treatment of neurodegenerative and psychiatric disorders Leber hereditary optic neuropathy: current perspectives Brain repair: cell therapy in stroke Mesenchymal stem cell transplantation in multiple sclerosis Human mesenchymal stromal cell-mediated immunoregulation: mechanisms of action and clinical applications Progress of mesenchymal stem cell therapy for neural and retinal diseases Optimization of pre-transplantation conditions to enhance the efficacy of mesenchymal stem cells Prospects for therapeutic tolerance in humans.A Personalized Approach in Progressive Multiple Sclerosis: The Current Status of Disease Modifying Therapies (DMTs) and Future Perspectives Mesenchymal stem cell therapy in retinal and optic nerve diseases: An update of clinical trials Multiple Sclerosis and Obesity: Possible Roles of Adipokines Inflammation converts human mesoangioblasts into targets of alloreactive immune responses: implications for allogeneic cell therapy of DMD Concise review: modeling multiple sclerosis with stem cell biological platforms: toward functional validation of cellular and molecular phenotypes in inflammation-induced neurodegeneration Primary progressive multiple sclerosis: current therapeutic strategies and future perspectives Imaging outcomes for trials of remyelination in multiple sclerosis.Vision and vision-related outcome measures in multiple sclerosis.Distribution pattern following systemic mesenchymal stem cell injection depends on the age of the recipient and neuronal health Treatment strategies for inherited optic neuropathies: past, present and future Transdifferentiation of autologous bone marrow cells on a collagen-poly(ε-caprolactone) scaffold for tissue engineering in complete lack of native urothelium.Pluripotent Nontumorigenic Adipose Tissue-Derived Muse Cells have Immunomodulatory Capacity Mediated by Transforming Growth Factor-β1.Are nestin-positive mesenchymal stromal cells a better source of cells for CNS repair?How stem cells speak with host immune cells in inflammatory brain diseases Mesenchymal stem or stromal cells: a review of clinical applications and manufacturing practices.The role of immune cells, glia and neurons in white and gray matter pathology in multiple sclerosis.A Distinct Subpopulation of Bone Marrow Mesenchymal Stem Cells, Muse Cells, Directly Commit to the Replacement of Liver Components.Randomized placebo-controlled phase II trial of autologous mesenchymal stem cells in multiple sclerosis.Phenotype, donor age and gender affect function of human bone marrow-derived mesenchymal stromal cells CD105 (endoglin)-negative murine mesenchymal stromal cells define a new multipotent subpopulation with distinct differentiation and immunomodulatory capacities Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives Mesenchymal stem cell-based therapy in a mouse model of experimental autoimmune encephalomyelitis (EAE)Mesenchymal stem cells augment the anti-bacterial activity of neutrophil granulocytes.Mesenchymal stem cells and induced pluripotent stem cells as therapies for multiple sclerosis.Adipose-Derived Mesenchymal Stem Cells Restore Impaired Mucosal Immune Responses in Aged Mice Mesenchymal stem/stromal cells-a key mediator for regeneration after perinatal morbidity?The potential of mesenchymal stromal cells as a novel cellular therapy for multiple sclerosis.Mechanical fibrinogen-depletion supports heparin-free mesenchymal stem cell propagation in human platelet lysate

P2860

Q24632756-93ABD0C9-56D5-4152-ADD2-6775AF849854 Q26750597-CFA6A588-6AD9-4C9A-BE09-2714B28A678E Q26765843-9AF70F6B-4C2A-4E97-B8F0-AC5121B4DCF0 Q26770191-6CB22D8F-3DAE-40ED-BE9C-C6A51F955ACD Q26801575-E417EFDA-4305-42D4-97ED-F7ECEC0D4092 Q26863599-96019B3C-1AF7-4FC5-85DF-1608B96E6325 Q26866330-05E45212-19F6-41AC-9DAD-2D1E9577B7A1 Q26999783-75DA5D4B-BF73-4F15-9D66-2C30C94594AF Q27004008-9876C7BD-E12C-4833-9629-8E7EB6AF5323 Q27015716-594CF9CE-20DF-413D-9A6A-D21DA7933C11 Q27015774-5DE123A1-2F5D-4A7A-9C01-D13DBE61056D Q27318199-689EF57F-1291-473A-93D6-368930C33846 Q28068709-535B7042-EB09-434F-83D2-544527FD6F6D Q28072497-C3421EF5-A9AA-4E72-8540-517A7CC20E64 Q28078518-059E292F-DFD1-4AB9-A43B-398320FB3F51 Q28389778-38BD3361-BD68-4930-BAB1-90FCF4B36DFD Q28649438-5B0F39A6-124C-4ED2-B7CB-BC003C378680 Q29030703-0F3B055D-0CE8-4901-8DD2-65937F7FCB58 Q30620892-2A78C5F9-904E-43FB-885E-91AE5A65413A Q30872452-5065D5E8-F0A1-471B-820E-2E88EA45F02B Q33576818-1CE896F4-FADD-4F59-9E70-A6D7C6B59D13 Q33595163-B6E5E278-0CCC-4DBE-B39F-070E7A582D36 Q33656032-4B2F8A03-9049-499B-AAD5-4F49DBADD629 Q33722118-75A3A256-F2EC-41AD-9A47-9823AA948576 Q33757255-44E5A048-E78D-4A7A-B1B7-42D597718290 Q33776557-66D17E97-5D54-4FB9-8A82-19055AC17794 Q34422955-3B183D18-7949-4F08-959D-FF709222D259 Q34468304-2D964038-8823-47D0-8317-92A9B86A2595 Q34504983-C053FBDE-6EE8-406E-8B50-79D758AC3BAA Q34600820-42C27B93-A805-4549-ACE1-C47D9C65594A Q34768188-E7AA99B1-588E-4633-B9C0-AAFBB7EC3F50 Q35017103-6F252CB7-C5AA-4350-BA0D-DC5A83640C57 Q35182733-405CFE76-4FFE-44AA-AC23-12FEAE3214BA Q35213818-58288C1C-E954-40CD-B2FC-8674F4114A81 Q35264761-D661F011-B5A7-43A2-AC7A-DDC46E4A34DF Q35722755-D9DC2FE3-43C3-4878-8CCF-288F10E3A0AC Q35912989-C91ED112-04F6-45E4-96D3-2DA78BE1F03D Q35921652-D2185F66-5904-47C9-8C46-A8AEADAD4264 Q36054671-B4E5663D-BA67-4539-9835-E5AAF349A0D4 Q36270533-9E50B13B-B2D4-4A4B-881E-3B929A022D79

P2860

Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study.

http://www.wikidata.org/entity/Q35757641

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Autologous mesenchymal stem ce ...... ase 2a proof-of-concept study.

@ast

Autologous mesenchymal stem ce ...... ase 2a proof-of-concept study.

@en

type

label

Autologous mesenchymal stem ce ...... ase 2a proof-of-concept study.

@ast

Autologous mesenchymal stem ce ...... ase 2a proof-of-concept study.

@en

prefLabel

Autologous mesenchymal stem ce ...... ase 2a proof-of-concept study.

@ast

Autologous mesenchymal stem ce ...... ase 2a proof-of-concept study.

@en

P1433

Q35757641-BD5A08CB-8FDF-4B37-AB54-13B5EAC7CB36

P1476

Q35757641-046EDF69-E67E-4D70-BDD4-C3459F2A115C

P2093

Q35757641-2867B324-CCCC-451A-B870-F6B11878CCC6

Q35757641-55F6CEE2-26EE-4FE6-B04A-341CC3441F3F

Q35757641-80E7087B-B57C-4262-8745-C391D18F9FF3

Q35757641-8E8177BF-8755-4DFC-A829-14F5DE346030

Q35757641-A63D1A13-5174-48E5-B48A-F626305410DD

Q35757641-AF7F8A24-4FEF-4FDF-BD27-26162636B1CE

Q35757641-B1A05C17-CFC1-42F6-9FF7-438712546BDE

Q35757641-B691A891-1FC8-451C-B35D-7FFEAA0B4C71

Q35757641-BE6CFC77-A42F-4E51-A5A4-6C95249D25E3

Q35757641-EBA40B84-5EB4-4D26-BF5B-48E7AB35DFCC

P2860

Q35757641-01FC971B-C06C-4363-A117-A17E074D0641

Q35757641-0A6893A3-6C14-4F17-A723-0100AA40D768

Q35757641-18F3D737-1F9E-4FD3-8E4F-C8C54C2C1F71

Q35757641-1EE0464D-917F-4956-8CFD-AD1194D68CF6

Q35757641-23066C51-7E3A-4B75-B46E-E8FD2902B1E8

Q35757641-540C3317-A5C1-45D1-8241-C452BE7CD927

Q35757641-5A9643A4-B826-4AF4-A2F9-398442156351

Q35757641-5B73CC5F-B78E-4E50-8983-D59EE1ABFDBF

Q35757641-6C301C67-130B-4780-A726-C2EF989B9714

Q35757641-6D15F4DC-0B9A-47F0-9296-67C99D49907A

P304

Q35757641-3EEE09EF-A0C1-415C-B265-06783A5BFC46

P31

Q35757641-8148E2D3-AED9-4529-BAC3-5017137EA2FA

P356

Q35757641-8BDD4EFB-8772-4297-85BF-50C48892B920

P433

Q35757641-301AA944-DB02-4F94-A46E-4670A8E9E015

P478

Q35757641-5ADA1C21-187A-4658-A7C8-FBD78FE423C6

P50

Q35757641-2D6D5A9A-8554-4286-AFF7-710D2AC1183A

Q35757641-64A6EF50-304F-4F2A-8798-D499CE57381A

Q35757641-975778F9-9D40-4CEC-B0E6-1E1B315FC7C4

Q35757641-BEA165DC-5B05-4795-9387-F31C56024E2E

P577

Q35757641-4F9296A6-46DC-4CCF-A2B1-754EFC1444A5

P698

Q35757641-8B41CF8A-B92B-499A-A582-C923C48EB08B

P921

Q35757641-CB10AE63-5FD6-4AB8-85B3-ADC12882263D

Q35757641-ECDB62FB-0362-4357-9D0D-0231B7B9FA92

P932

Q35757641-53455587-155E-4B1D-B620-6E26C18619AF

P356

S1474-4422(11)70305-2

P1433

Lancet Neurology

P1476

Autologous mesenchymal stem ce ...... ase 2a proof-of-concept study.

@en

P2093

Andrew W Michell

http://www.w3.org/2001/XMLSchema#string

Charles Crawley

http://www.w3.org/2001/XMLSchema#string

Daniel J Webber

http://www.w3.org/2001/XMLSchema#string

Daniel R Altmann

http://www.w3.org/2001/XMLSchema#string

David H Miller

http://www.w3.org/2001/XMLSchema#string

Madhan Kolappan

http://www.w3.org/2001/XMLSchema#string

Michael A Scott

http://www.w3.org/2001/XMLSchema#string

Ming-Qing Du

http://www.w3.org/2001/XMLSchema#string

Shi-Lu Luan

http://www.w3.org/2001/XMLSchema#string

Siddharthan Chandran

http://www.w3.org/2001/XMLSchema#string

P2860

Defining the clinical course of multiple sclerosis: Results of an international survey

Multilineage potential of adult human mesenchymal stem cells

Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement

Multiple sclerosis

Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study

Remyelination in the CNS: from biology to therapy

Alemtuzumab vs. interferon beta-1a in early multiple sclerosis.

Assessing structure and function of the afferent visual pathway in multiple sclerosis and associated optic neuritis.

Application of array CGH on archival formalin-fixed paraffin-embedded tissues including small numbers of microdissected cells.

Bone marrow mesenchymal stem cell transplantation in patients with multiple sclerosis: a pilot study.

P304

150-156

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S1474-4422(11)70305-2

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P50

Alastair Compston

Alan J Thompson

P577

2012-01-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22236384

http://www.w3.org/2001/XMLSchema#string

P921

secondary progressive multiple sclerosis

multiple sclerosis

P932

3279697

http://www.w3.org/2001/XMLSchema#string